AHA yesterday sent a letter to the Department of Justice’s Antitrust Division expressing its serious concern with the adequacy of any remedy to resolve the anticompetitive impact of UnitedHealth Group’s acquisition of Change Healthcare. UHG in January announced its intent to combine its Optum health services subsidiary with Change Healthcare, a health care technology firm, to provide software and data analytics, technology-enabled services and research, advisory and revenue cycle management services.

At the time, AHA argued that the deal would distort “decisions about patient care and claims processing and denials to the detriment of consumers and health care providers and further increase UHG’s already massive market power.” In the newest letter AHA reiterated that “it is highly unlikely that any remedy will preserve the substantial level of competition between the parties that will be lost if the transaction is completed.”

Headline
The AHA Aug. 28 shared concerns with the Centers for Medicare & Medicaid Services regarding the calendar year 2027 hospital outpatient prospective payment…
Headline
The AHA provided comments to the Centers for Medicare & Medicaid Services Aug. 28 on its calendar year 2027 home health prospective payment system proposed…
Headline
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act),…
Headline
The Department of Homeland Security today released a proposed rule to establish a new $103,265 filing fee for H-1B visa petitions that are subject to statutory…
Headline
President Trump announced Aug. 19 that he has nominated Heidi Overton to serve as the next commissioner of the Food and Drug Administration. Overton currently…
Headline
The 5th U.S. Circuit Court of Appeals Aug. 11 ruled to vacate certain regulations implementing how the No Surprises Act qualifying payment amount is calculated…